Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 7/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292751 | 0.85 | THRA (0.40) | THRATHRBFFAR4SCN8ANR3C1 | |
| SCHEMBL2293180 | 0.84 | SCN8A (0.35) | FFAR4SCN8AFFAR1NR3C1MEN1 | |
| SCHEMBL2290246 | 0.80 | MAPT (0.41) | THRATHRBFFAR4SCN8AFFAR1 | |
| SCHEMBL2293423 | 0.80 | THRA (0.38) | THRATHRBFFAR4SCN8AFFAR1 | |
| SCHEMBL27777987 | 0.78 | FFAR4 (0.37) | THRATHRBFFAR4SCN8AFFAR1 | |
| SCHEMBL2290430 | 0.77 | THRA (0.40) | THRATHRBFFAR4SCN8AMEN1 | |
| SCHEMBL2290297 | 0.76 | THRA (0.40) | THRATHRBFFAR4SCN8AFFAR1 | |
| SCHEMBL2292381 | 0.75 | PTPN1 (0.33) | — | |
| SCHEMBL2287492 | 0.75 | THRA (0.38) | THRATHRBFFAR4SCN8AFFAR1 | |
| SCHEMBL2293554 | 0.75 | THRA (0.39) | THRATHRBFFAR4SCN8AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149545-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-7994367-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2149545-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, C9, TRPA1 | THRA 3834/4885THRB 4314/4885FFAR4 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.